Ireland
--:--IST
Latest
Clinical Trials in France / NCT07666880
Starting soon Not applicable

Hemodynamic Impact of the Spontaneous Ventilation Test in Patients at Risk of Weaning Pulmonary Oedema

NCT07666880 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-08-01
Last updated
2026-06-24

Condition(s) studied

Weaning-induced Pulmonary Edema

Investigational drug(s) / intervention(s)

T-piece SBTPS-ZEEP SBT

T-piece SBT: T-piece SBT will be evaluated first and PS-ZEEP SBT in a second time. If the first SBT fails, regardless of the modality used or the cause of failure, the second SBT will not be performed. The patient will then be managed according to the participating centers' standard of care (treatment guided by the main mechanism of WIPE identified by echocardiography). The two SBTs will be separated by at least 6 hours, during which no therapeutic changes will be made (in case of success at the first SBT). This interval corresponds to the usual SBT schedule (typically one SBT in the morning and one in the afternoon).

PS-ZEEP SBT: In this arm, PS-ZEEP SBT will be evaluated first and T-piece SBT ina second time. If the first SBT fails, regardless of the modality used or the cause of failure, the second SBT will not be performed. The patient will then be managed according to the participating centers' standard of care (treatment guided by the main mechanism of WIPE identified by echocardiography). The two SBTs will be separated by at least 6 hours, during which no therapeutic changes will be made (in case of success at the first SBT). This interval corresponds to the usual SBT schedule (typically one SBT in the morning and one in the afternoon).

Study summary

Weaning-induced pulmonary edema (WIPE) from the ventilator is a frequent cause of extubation failure or delay, which prolongs the duration of invasive mechanical ventilation and the associated morbidity and mortality. WIPE is a very frequent cause of extubation failure in at-risk patients. A spontaneous breathing trial (SBT) is performed before extubating a patient, either by disconnecting the patient from the ventilator (T-piece SBT) or by setting the ventilator to spontaneous breathing mode with pressure support at 7 cm H2O and zero positive end-expiratory pressure (PS-ZEEP SBT). There is currently no recommendation regarding which SBT modality should be used, particularly in patients at risk of WIPE. The hemodynamic changes induced by the SBT can lead to WIPE, which typically develops within minutes of the SBT onset.

The hypothesis being tested is that, by altering intrathoracic pressure during the patient's inspiration (negative pressure), the T-piece SBT leads to a greater increase in left ventricular filling pressures compared to the PS-ZEEP SBT.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patient (\> 18 years) on invasive mechanical ventilation in the ICU for more than 48 hours * In the ventilator weaning phase with a first SBT planned * At risk of WIPE: age over 65 years and/or any type of heart disease and/or chronic respiratory failure and/or obesity Exclusion Criteria: * Patient who has already participated in the study * No transthoracic echocardiographic images suitable for analysis * Non-sinus rhythm (including pacemaker) * Tracheostomy * Chronic neuromuscular or neurodegenerative disease * Persons deprived of liberty or under legal protection * Pregnant or breastfeeding woman

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Ambroise Paré Hospital -APHP Boulogne-Billancourt France
Limoges University hospital Limoges France
Nice University Hospital - Archet Nice France
Nice university hospital - Pasteur Nice France

More University Hospital, Limoges trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07666880 on ClinicalTrials.gov ↗ ← All trials in France